| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abatacept for IgG4-related disease: therapeutic prospects according to disease immunophenotype
|
Peng, Yu
|
|
|
|
2 |
p. e75-e76
|
artikel
|
| 2 |
Abatacept in IgG4-related disease: a prospective, open-label, single-arm, single-centre, proof-of-concept study
|
Matza, Mark A
|
|
|
|
2 |
p. e105-e112
|
artikel
|
| 3 |
Allogeneic mesenchymal stromal cell transplantation for systemic sclerosis
|
Volkmann, Elizabeth R
|
|
|
|
2 |
p. e74-e75
|
artikel
|
| 4 |
Arthritis mutilans in juvenile idiopathic arthritis
|
Miyamae, Takako
|
|
|
|
2 |
p. e160
|
artikel
|
| 5 |
Association of economic insecurities with patient-reported outcomes in systemic lupus erythematosus
|
Valle, Ana
|
|
|
|
2 |
p. e68-e70
|
artikel
|
| 6 |
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study
|
Kronzer, Vanessa L
|
|
|
|
2 |
p. e77-e87
|
artikel
|
| 7 |
Barriers to translational research in Sjögren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease
|
Ciurtin, Coziana
|
|
|
|
2 |
p. e138-e148
|
artikel
|
| 8 |
Big Little Lies: challenging misperceptions of gout
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e75
|
artikel
|
| 9 |
Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics
|
Stefanov, Kristian
|
|
|
|
2 |
p. e99-e109
|
artikel
|
| 10 |
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
|
Md Yusof, Md Yuzaiful
|
|
|
|
2 |
p. e88-e98
|
artikel
|
| 11 |
Cannonball opacities in a pregnant woman
|
Mittal, Sakshi
|
|
|
|
2 |
p. e132
|
artikel
|
| 12 |
Cardiac myxoma mimicking a spondyloarthritis flare
|
Delmotte, Anastasia
|
|
|
|
2 |
p. e128
|
artikel
|
| 13 |
Changing COVID-19 outcomes in patients with rheumatic disease—are we really getting better at this?
|
Gianfrancesco, Milena A
|
|
|
|
2 |
p. e88-e90
|
artikel
|
| 14 |
Clinical medical education under circumstances of war
|
Novick, Adrienne Feller
|
|
|
|
2 |
p. e65
|
artikel
|
| 15 |
Clinical trial design: time to accelerate the pace of change?
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e59
|
artikel
|
| 16 |
Consensus statements for managing systemic sclerosis-associated interstitial lung disease
|
Proudman, Susanna
|
|
|
|
2 |
p. e64-e65
|
artikel
|
| 17 |
Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts
|
Belot, Alexandre
|
|
|
|
2 |
p. e99-e109
|
artikel
|
| 18 |
Correction to Lancet Rheumatol 2021; 3: e71–82
|
|
|
|
|
2 |
p. e99
|
artikel
|
| 19 |
David Liew: where communication meets medicine
|
Burton, Adrian
|
|
|
|
2 |
p. e90
|
artikel
|
| 20 |
Disease activity markers for SLE: is a little activity more helpful than none?
|
Wallace, Daniel J
|
|
|
|
2 |
p. e77-e79
|
artikel
|
| 21 |
Distinct immune response to CoronaVac in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic disease
|
Gao, Xing-Su
|
|
|
|
2 |
p. e77-e78
|
artikel
|
| 22 |
Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study
|
Sandoval-Heglund, Donavon
|
|
|
|
2 |
p. e105-e114
|
artikel
|
| 23 |
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
|
Abhishek, Abhishek
|
|
|
|
2 |
p. e92-e104
|
artikel
|
| 24 |
Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial
|
Redl, Anna
|
|
|
|
2 |
p. e81-e91
|
artikel
|
| 25 |
Efficacy matters: broadening complement inhibition in COVID-19
|
Mastellos, Dimitrios C
|
|
|
|
2 |
p. e95
|
artikel
|
| 26 |
Efficacy matters: broadening complement inhibition in COVID-19 – Authors' reply
|
Vlaar, Alexander P J
|
|
|
|
2 |
p. e95-e96
|
artikel
|
| 27 |
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study
|
Golder, Vera
|
|
|
|
2 |
p. e103-e110
|
artikel
|
| 28 |
Expanding the inventory of rare variants in SLE
|
Alarcón-Riquelme, Marta E
|
|
|
|
2 |
p. e67-e69
|
artikel
|
| 29 |
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort study
|
Garcia-Montoya, Leticia
|
|
|
|
2 |
p. e72-e80
|
artikel
|
| 30 |
Fighting flu: the importance of vaccines in rheumatic disease
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e63
|
artikel
|
| 31 |
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19
|
Garbers, Christoph
|
|
|
|
2 |
p. e96-e97
|
artikel
|
| 32 |
Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 – Authors' reply
|
Bovijn, Jonas
|
|
|
|
2 |
p. e97-e98
|
artikel
|
| 33 |
How can we prevent dislocations after total hip arthroplasty?
|
Chen, Antonia F
|
|
|
|
2 |
p. e79-e80
|
artikel
|
| 34 |
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
|
Shenoy, Padmanabha
|
|
|
|
2 |
p. e80-e82
|
artikel
|
| 35 |
Hydroxychloroquine-induced bull's eye maculopathy
|
Pellerano, Fernando
|
|
|
|
2 |
p. e120
|
artikel
|
| 36 |
Idiopathic inflammatory myopathies: current insights and future frontiers
|
Connolly, Caoilfhionn M
|
|
|
|
2 |
p. e115-e127
|
artikel
|
| 37 |
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
|
Aikawa, Nadia E
|
|
|
|
2 |
p. e113-e124
|
artikel
|
| 38 |
Immunomodulatory and immunosuppressive medication modification among patients with rheumatic diseases at the time of COVID-19 vaccination
|
Barbhaiya, Medha
|
|
|
|
2 |
p. e85-e87
|
artikel
|
| 39 |
Improving COVID-19 vaccine response in individuals receiving methotrexate
|
Bechman, Katie
|
|
|
|
2 |
p. e67-e68
|
artikel
|
| 40 |
Industry involvement in rheumatology consensus-based recommendations: a systematic review
|
Feterman Jimenez, Dominique
|
|
|
|
2 |
p. e145-e152
|
artikel
|
| 41 |
Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?
|
Murray, Grainne M
|
|
|
|
2 |
p. e90-e92
|
artikel
|
| 42 |
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
|
Golder, Vera
|
|
|
|
2 |
p. e95-e102
|
artikel
|
| 43 |
Making the right thing the easy thing to do: strategies to improve outcomes in gout
|
Dalbeth, Nicola
|
|
|
|
2 |
p. e122-e131
|
artikel
|
| 44 |
Mental health before and during the pandemic in people with systemic sclerosis
|
Henry, Richard S
|
|
|
|
2 |
p. e82-e85
|
artikel
|
| 45 |
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
|
Sheikh, Saira Z
|
|
|
|
2 |
p. e122-e130
|
artikel
|
| 46 |
Navigating use of rituximab during the COVID-19 pandemic
|
Elahee, Mehreen
|
|
|
|
2 |
p. e63-e64
|
artikel
|
| 47 |
Novel COVID-19 therapies: the road ahead for rheumatology
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e73
|
artikel
|
| 48 |
Pandemic to endemic: optimising COVID-19 immunity
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e63
|
artikel
|
| 49 |
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study
|
Shoop-Worrall, Stephanie J W
|
|
|
|
2 |
p. e111-e121
|
artikel
|
| 50 |
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
|
Bruce, Ian N
|
|
|
|
2 |
p. e101-e110
|
artikel
|
| 51 |
Predicting rheumatoid arthritis-associated interstitial lung disease: filling the void
|
Hutchinson, David
|
|
|
|
2 |
p. e61-e63
|
artikel
|
| 52 |
Predicting the risk of needing a total knee arthroplasty
|
Clement, Nick D
|
|
|
|
2 |
p. e78-e79
|
artikel
|
| 53 |
Prediction models for the risk of total knee replacement: development and validation using data from multicentre cohort studies
|
Liu, Qiang
|
|
|
|
2 |
p. e125-e134
|
artikel
|
| 54 |
Preventing myofibre necrosis in immune-mediated necrotising myopathy—is complement inhibition effective?
|
Limaye, Vidya Sadanand
|
|
|
|
2 |
p. e60-e61
|
artikel
|
| 55 |
Professional empathy from personal experience
|
Burki, Talha Khan
|
|
|
|
2 |
p. e84
|
artikel
|
| 56 |
Pseudoxanthomatous rheumatoid nodule
|
Horino, Taro
|
|
|
|
2 |
p. e110
|
artikel
|
| 57 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
2 |
p. e100
|
artikel
|
| 58 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
2 |
p. e88
|
artikel
|
| 59 |
Research in Brief
|
Van Epps, Heather
|
|
|
|
2 |
p. e83
|
artikel
|
| 60 |
Research in Brief
|
Brooks, Helen
|
|
|
|
2 |
p. e70
|
artikel
|
| 61 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
2 |
p. e66
|
artikel
|
| 62 |
Research in Brief
|
Thorley, Jennifer
|
|
|
|
2 |
p. e71
|
artikel
|
| 63 |
Rheumatoid arthritis, then and now
|
Michell, Bob
|
|
|
|
2 |
p. e89
|
artikel
|
| 64 |
Risk factors for dislocation after primary total hip replacement: a systematic review and meta-analysis of 125 studies involving approximately five million hip replacements
|
Kunutsor, Setor K
|
|
|
|
2 |
p. e111-e121
|
artikel
|
| 65 |
Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study
|
Pawar, Ajinkya
|
|
|
|
2 |
p. e84-e98
|
artikel
|
| 66 |
Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study
|
Farge, Dominique
|
|
|
|
2 |
p. e91-e104
|
artikel
|
| 67 |
Subclinical synovitis: let's discuss prognosis before treatment
|
Yalcin-Mutlu, Melek
|
|
|
|
2 |
p. e64-e65
|
artikel
|
| 68 |
Subcutaneous anifrolumab for SLE: a new step forward?
|
Costedoat-Chalumeau, Nathalie
|
|
|
|
2 |
p. e84-e85
|
artikel
|
| 69 |
Symptom-based stratification of autoimmune diseases
|
Idborg, Helena
|
|
|
|
2 |
p. e76-e77
|
artikel
|
| 70 |
Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
|
Tarn, Jessica R
|
|
|
|
2 |
p. e85-e94
|
artikel
|
| 71 |
Systemic lupus erythematosus: diverting progress to chase rare side effects?
|
Merrill, Joan T
|
|
|
|
2 |
p. e87-e88
|
artikel
|
| 72 |
Targeting mTOR in sarcoid granulomas: where the rubber meets the road
|
Morgenthau, Adam S
|
|
|
|
2 |
p. e65-e66
|
artikel
|
| 73 |
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
|
Jorge, April
|
|
|
|
2 |
p. e131-e137
|
artikel
|
| 74 |
The controversial role of wellbeing assessment in juvenile idiopathic arthritis
|
Santaniello, Stefania
|
|
|
|
2 |
p. e85-e86
|
artikel
|
| 75 |
The crisis of inadequate treatment in osteoporosis
|
Roux, Christian
|
|
|
|
2 |
p. e110-e119
|
artikel
|
| 76 |
The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
|
Hoffmann-Vold, Anna-Maria
|
|
|
|
2 |
p. e71-e83
|
artikel
|
| 77 |
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis
|
Bruni, Cosimo
|
|
|
|
2 |
p. e149-e159
|
artikel
|
| 78 |
The plight and light of treating rheumatoid arthritis in China
|
Xie, Wenhui
|
|
|
|
2 |
p. e81-e82
|
artikel
|
| 79 |
Therapeutic implications of ongoing alveolar viral replication in COVID-19
|
McGonagle, Dennis
|
|
|
|
2 |
p. e135-e144
|
artikel
|
| 80 |
Tofacitinib's infectious profile: concerns for clinical practice
|
Favalli, Ennio Giulio
|
|
|
|
2 |
p. e65-e67
|
artikel
|
| 81 |
Too long to wait: the impact of COVID-19 on elective surgery
|
The Lancet Rheumatology,
|
|
|
|
2 |
p. e83
|
artikel
|
| 82 |
Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice
|
Mehta, Puja
|
|
|
|
2 |
p. e92-e94
|
artikel
|
| 83 |
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
|
Mammen, Andrew L
|
|
|
|
2 |
p. e67-e76
|
artikel
|
Tijdschrift beschrijving